LOX Expression and Functional Analysis in Astrocytomas and Impact of IDH1 Mutation

Imagem de Miniatura
Arquivos
art_SILVA_LOX_Expression_and_Functional_Analysis_in_Astrocytomas_and_2015.PDF (3.21 MB)
Citações na Scopus
44
Tipo de produção
article
Data de publicação
2015
Editora
PUBLIC LIBRARY SCIENCE
DOI
Indexadores
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Autores
Autor de Grupo de pesquisa
Editores
Coordenadores
Organizadores
Citação
PLOS ONE, v.10, n.3, article ID e0119781, 18p, 2015
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Lysyl oxidase (LOX) is involved in vital biological processes such as cell motility, cell signaling and gene regulation. Deregulation of this protein can contribute to tumor formation and progression. Although it is known that LOX is involved in invasion, proliferation and tumor migration in other types of tumors, studies of LOX in astrocytomas of different grades are scarce. The purpose of our study was to characterize LOX, BMP1 and HIF1A expression by real-time PCR in astrocytomas with WHO grades I to IV compared to non-neoplastic brain tissue. IDH1 mutational status was determined by PCR and sequencing. LOX protein expression was also analyzed by immunohistochemistry. LOX functional analyses were performed using siRNA knockdown and the specific inhibitor BAPN in two glioblastoma cell lines. The expression levels of LOX, BMP1 and HIF1A were correlated and analyzed according to IDH1 mutation status and to the clinical end-point of overall survival of glioblastoma patients. The results demonstrate that increased expression and activity of LOX, BMP1 and HIF1A were positively correlated with the malignant grade of astrocytomas. LOX protein expression also increased according to the degree of malignancy, with localization in the cytoplasm and nucleus and staining observed in endothelial cells. Glioblastoma with a mutation in IDH1 expressed lower levels of LOX in the nucleus, and IDH1-mutated cases showed lower LOX expression levels when compared to wild-type IDH1 cases. LOX knockdown and inhibition by BAPN in U87MG and A172 cell lines affected migration, invasion and soft agar colony formation. Taken together, these results corroborate the role of LOX in the migration, invasion and angiogenesis of astrocytomas. Furthermore, LOX expression is influenced by IDH1 mutational status. This work provides new insights for researchers aiming to design targeted therapies to control astrocytomas.
Palavras-chave
URI
https://observatorio.fm.usp.br/handle/OPI/9808
Referências
  1. Abourbih DA, 2010, MELANOMA RES, V20, P97, DOI 10.1097/CMR.0b013e328336edfe
  2. Albinger-Hegyi A, 2010, INT J CANCER, V126, P2653, DOI 10.1002/ijc.24948
  3. AREM AJ, 1975, SURG FORUM, V26, P67
  4. Baker AM, 2013, CANCER RES, V73, P583, DOI 10.1158/0008-5472.CAN-12-2447
  5. Baker AM, 2011, J NATL CANCER I, V103, P407, DOI 10.1093/jnci/djq569
  6. Balss J, 2008, ACTA NEUROPATHOL, V116, P597, DOI 10.1007/s00401-008-0455-2
  7. Basuroy S, 2010, AM J PHYSIOL-GASTR L, V299, pG186, DOI 10.1152/ajpgi.00368.2009
  8. Bleeker FE, 2009, HUM MUTAT, V1, P7
  9. BOND JS, 1995, PROTEIN SCI, V4, P1247
  10. Bondareva A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005620
  11. Carvalho PO, 2014, INT J BIOL MARKER, V29, pE120, DOI 10.5301/JBM.5000045
  12. Chen LC, 2012, BREAST CANCER RES TR, V134, P989, DOI 10.1007/s10549-012-1986-8
  13. Chesnelong C, 2013, NEURO-ONCOLOGY, V16, P686, DOI [10.1093/ neuonc/ not243, DOI 10.1093/NEU0NC/N0T243]
  14. Cox TR, 2011, DIS MODEL MECH, V4, P165, DOI 10.1242/dmm.004077
  15. Csiszar K, 2001, PROG NUCLEIC ACID RE, V70, P1, DOI 10.1016/S0079-6603(01)70012-8
  16. Dong YY, 2014, BIOCHEM BIOPH RES CO, V444, P427, DOI 10.1016/j.bbrc.2014.01.079
  17. El-Osta A, 2000, GENE EXPRESSION, V9, P63
  18. Erler JT, 2006, NATURE, V440, P1222, DOI 10.1038/nature04695
  19. Erler JT, 2009, CLIN EXP METASTAS, V26, P35, DOI 10.1007/s10585-008-9209-8
  20. Ge Gaoxiang, 2006, Birth Defects Research, V78, P47, DOI 10.1002/bdrc.20060
  21. Gravendeel LAM, 2010, HUM MUTAT, V31, pE1186, DOI 10.1002/humu.21201
  22. Ichimura K, 2009, NEURO-ONCOLOGY, V11, P341, DOI 10.1215/15228517-2009-025
  23. Ji F, 2013, INT J ONCOL, V42, P1578, DOI 10.3892/ijo.2013.1878
  24. KAGAN HM, 1991, AM J RESP CELL MOL, V5, P206
  25. Kagan HM, 2003, J CELL BIOCHEM, V88, P660, DOI 10.1002/jcb.10413
  26. Kaneda A, 2004, CANCER RES, V64, P6410, DOI 10.1158/0008-5472.CAN-04-1543
  27. Kessler E, 1996, SCIENCE, V271, P360, DOI 10.1126/science.271.5247.360
  28. Kirschmann DA, 2002, CANCER RES, V62, P4478
  29. Laczko R, 2007, NEUROPATH APPL NEURO, V33, P631, DOI 10.1111/j.1365-2990.2007.00858.x
  30. Lai A, 2011, J CLIN ONCOL, V29, P4482, DOI 10.1200/JCO.2010.33.8715
  31. Lazarus HM, 1995, MATRIX BIOL, V14, P727, DOI 10.1016/S0945-053X(05)80015-0
  32. Lee K, 2006, CHEM RES TOXICOL, V19, P1284, DOI 10.1021/tx060068d
  33. Levental KR, 2009, CELL, V139, P891, DOI 10.1016/j.cell.2009.10.027
  34. Li PA, 2004, MOL BRAIN RES, V120, P115, DOI 10.1016/j.molbrainres.2003.10.013
  35. Li WD, 1997, P NATL ACAD SCI USA, V94, P12817, DOI 10.1073/pnas.94.24.12817
  36. Louis DN, 2007, ACTA NEUROPATHOL, V114, P97, DOI 10.1007/s00401-007-0243-4
  37. Mammoto T, 2013, AM J PATHOL, V183, P1293, DOI 10.1016/j.ajpath.2013.06.026
  38. Maruhashi T, 2010, J BIOL CHEM, V285, P13294, DOI 10.1074/jbc.M109.088864
  39. Mustafa D, 2013, J NEUROPATHOL EXP NE, V7, P1171
  40. Nellaiappan K, 2000, J CELL BIOCHEM, V79, P576, DOI 10.1002/1097-4644(20001215)79:4<576::AID-JCB60>3.0.CO;2-A
  41. Nishioka T, 2012, CELL STRUCT FUNCT, V37, P75
  42. Nobusawa S, 2009, CLIN CANCER RES, V15, P6002, DOI 10.1158/1078-0432.CCR-09-0715
  43. Noushmehr H, 2010, CANCER CELL, V17, P510, DOI 10.1016/j.ccr.2010.03.017
  44. Ohgaki H, 2013, CLIN CANCER RES, V19, P764, DOI 10.1158/1078-0432.CCR-12-3002
  45. Ohgaki H, 2011, BRAIN TUMOR PATHOL, V28, P177, DOI 10.1007/s10014-011-0029-1
  46. Osawa T, 2013, BRIT J CANCER, V109, P2237, DOI 10.1038/bjc.2013.535
  47. Parsons DW, 2008, SCIENCE, V321, P1807, DOI 10.1126/science.1164382
  48. Pez F, 2011, CANCER RES, V71, P1647, DOI 10.1158/0008-5472.CAN-10-1516
  49. Ping W, 2013, ASIAN PAC J CANCER P, V14, P3613, DOI 10.7314/APJCP.2013.14.6.3613
  50. Saad FA, 2010, BIOCHEM BIOPH RES CO, V396, P944, DOI 10.1016/j.bbrc.2010.05.028
  51. Sakai M, 2009, ANN SURG ONCOL, V16, P2494, DOI 10.1245/s10434-009-0559-5
  52. Schietke R, 2010, J BIOL CHEM, V285, P6658, DOI 10.1074/jbc.M109.042424
  53. Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73
  54. SHERIDAN PJ, 1979, EXP MOL PATHOL, V30, P315, DOI 10.1016/0014-4800(79)90063-7
  55. Shih YH, 2013, HEAD NECK-J SCI SPEC, V35, P250, DOI 10.1002/hed.22959
  56. Smith-Mungo LI, 1998, MATRIX BIOL, V16, P387, DOI 10.1016/S0945-053X(98)90012-9
  57. Sterchi EE, 2008, MOL ASPECTS MED, V29, P309, DOI 10.1016/j.mam.2008.08.002
  58. Stewart GD, 2008, ONCOL REP, V20, P1561, DOI 10.3892/or_00000180
  59. Uno M, 2005, CANCER LETT, V224, P321, DOI 10.1016/j.canlet.2004.10.022
  60. Uno M, 2011, CLINICS, V66, P163, DOI 10.1590/S1807-59322011000100028
  61. Watanabe T, 2009, AM J PATHOL, V174, P1149, DOI 10.2353/ajpath.2009.080958
  62. Weller M, 2011, GLIA, V59, P1200, DOI 10.1002/glia.21130
  63. Wiel C, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.382
  64. Yan H, 2009, NEW ENGL J MED, V360, P765, DOI 10.1056/NEJMoa0808710
  65. Yang XX, 2013, ONCOL REP, V29, P541, DOI 10.3892/or.2012.2146

Coleções
Artigos e Materiais de Revistas Científicas - FM/MNE
Artigos e Materiais de Revistas Científicas - HC/ICESP
Artigos e Materiais de Revistas Científicas - LIM/15
Artigos e Materiais de Revistas Científicas - ODS/03